Summary
Industry
Insights
Strolll, based in London, holds significant potential for its unique approach to treating Parkinson's disease through augmented reality (AR) therapy. Unlike conventional methods, Strolll's AR technology provides an interactive form of therapy that can improve symptom management and enhance patients' quality of life. Traditional treatments may lead to slower progress and reduced mobility, while Strolll's solution offers a more stimulating and effective experience. With backing from investors like SFC Capital and Kluz Ventures, Strolll is poised to make a notable impact in health tech by offering a patient-friendly alternative to standard Parkinson's treatments.
Investors
Martlet Capital Seed
SFC Capital Seed
Midlands Engine Investment Fund Seed
Kluz Ventures Pre Seed